English | 简体中文 | 繁體中文 | 한국어
 All Press Releases
 Medicine BioTech
Novotech 客戶 SK bioscience 在韓國獲得 SKYCovione(TM) COVID-19 疫苗批准
Jul 14, 2022 08:00 HKT
FDA Grants De Novo Marketing Authorization to Apollo Endosurgery for Apollo ESG and Apollo REVISE, New Endoscopic Systems for Patients with Obesity
Jul 13, 2022 19:30 HKT
Malaysian Genomics Forms Partnership for Expansion in Saudi Arabia
Jul 13, 2022 15:00 HKT
Novotech Client SK bioscience Achieves SKYCovione(TM) COVID-19 Vaccine Approval in Korea
Jul 13, 2022 14:30 HKT
SinoMab Received the Highest Subsidy from HKSTP
Jul 08, 2022 19:03 HKT
中国抗体获香港科学园最高专项补贴
Jul 08, 2022 19:01 HKT
中國抗體獲香港科學園最高專項補貼
Jul 08, 2022 19:00 HKT
Malaysian Genomics Proposes Private Placement
Jul 08, 2022 18:00 HKT
Co-led by Legend Capital, Huili Biotechnology Completes Series A Financing Round with Hundreds of Million RMB
Jul 07, 2022 19:13 HKT
Malaysian Genomics to Offer First-Ever Sports-Based Tests Specific to Southeast Asian Genetic Profiles
Jul 06, 2022 16:00 HKT
Avantor Named Best Company for Upstream Processing and Single-Use Solutions at BMK 2022
Jun 30, 2022 10:42 HKT
노보텍, 2022 코리아 바이오프로세싱 엑설런스 어워드에서 ‘2022년 최고 바이오로직스 CRO 어워드’ 수상
Jun 29, 2022 19:00 HKT
Oculis宣布首名患者參與OCS-01「OPTIMIZE」3期臨床試驗旨在治療白內障手術後炎症和疼痛
Jun 29, 2022 18:23 HKT
Oculis Announces First Patient Enrolled in Phase 3 OPTIMIZE Trial of OCS-01 in the Treatment of Inflammation and Pain Following Cataract Surgery
Jun 29, 2022 18:22 HKT
Novotech Receives "Best Biologics CRO Award 2022" at Korea Bioprocessing Excellence Awards 2022
Jun 29, 2022 07:00 HKT
Novotech在2022年韩国生物工艺卓越奖中获得“2022年最佳生物制剂CRO奖”
Jun 29, 2022 07:00 HKT
Novotech在2022年韓國生物工藝卓越獎中獲得“2022年最佳生物製劑CRO獎”
Jun 29, 2022 07:00 HKT
Novel patching material for bone defects
Jun 27, 2022 17:00 HKT
医思健康荣获《机构投资者》2022亚洲区最佳管理团队多个奖项
Jun 27, 2022 11:45 HKT
醫思健康榮獲《機構投資者》2022亞洲區最佳管理團隊多個獎項
Jun 27, 2022 11:44 HKT
<< Previous  Next >>
Copyright © 2024 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 214 890 4418 | Beijing: +86 400 879 3881 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575

Connect With us: